The safety and efficacy of intra-arterial low dose tirofiban administration during endovascular therapy in patients with large ischemic core volume

Abstract

Abstract This study aimed to evaluate the safety and efficacy of intra-arterial (IA) administration of low dose tirofiban during endovascular therapy in patients with large ischemic volumes on initial brain CT. Patients were divided into two groups based on the use of IA tirofiban. We identified 87 patients (16 and 71 patients in the tirofiban and no-tirofiban groups, respectively) with acute ischemic stroke due to intracranial artery occlusion who underwent endovascular therapy with a low Alberta Stroke Program Early CT scores (2–5). Multivariate logistic regression analysis revealed no association between IA tirofiban administration and serious postprocedural haemorrhagic complications (adjusted odds ratio (aOR), 0.720; 95% confidence interval (CI), 0.099–5.219; p = 0.960), any radiologic haemorrhage (aOR 0.076; 95% CI, 0.003–2.323; p = 0.139), or 3-month mortality (aOR, 0.087; 95% CI, 0.005–1.501; p = 0.093). However, IA tirofiban was associated with a lower 90-day mRS score (aOR, 0.197; 95% CI, 0.015–1.306; p = 0.017) and change in NIHSS score from baseline (aOR, 0.698; 95% CI, 0.531–0.917; p = 0.010). IA tirofiban administration during endovascular therapy in patients with large ischemic volumes may be effective and safe.